Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Rituximab in Secondary Progressive Multiple Sclerosis (ITT-PMS Extension)
2012-000721-53Phase 2Completed
- Sponsor
- Umeå University Hospital
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in secondary-progressive multiple sclerosis (SPMS), sponsored by Umeå University Hospital. Primary endpoint: Time to disability progression on EDSS. Started Oct 2012; status: completed.
02
Drugs
rituximab
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2012-000721-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000721-53.